Immunogenicity Negatively Influences the Outcome of Adalimumab Treatment in Crohn’s Disease

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/j.1365-2036.2008.03828.x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cost-Minimization Analysis of Infliximab Versus Adalimumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Treatment Perspectives in Crohn’s Disease

Digestion
Gastroenterology
2018English

Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2018English

Mycobacterial Infection Influences Bone Biomarker Levels in Crohn’s Disease

Canadian Journal of Physiology and Pharmacology
MedicinePhysiologyPharmacology
2018English

Primary Cutaneous Nocardiosis in a Patient Taking Adalimumab Therapy for Crohn’s Disease

Kansas Journal of Medicine
2019English

Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Certolizumab Pegol for the Treatment of Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2011English

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: The CLASSIC-I Trial

Gastroenterology
HepatologyGastroenterology
2006English

Dietary Treatment of Active Crohn’s Disease

Nursing standard (Royal College of Nursing (Great Britain) : 1987)
Medicine
1990English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy